Sichuan Biokin PharmaceuticalLtd Second Quarter 2024 Earnings: CN¥0.85 loss per share (vs CN¥0.40 loss in 2Q 2023)

Sichuan Biokin PharmaceuticalLtd (SHSE:688506) Second Quarter 2024 Results

Key Financial Results

• Revenue: CN¥90.6m (down 52% from 2Q 2023).
• Net loss: CN¥338.8m (loss widened by 110% from 2Q 2023).
• CN¥0.85 loss per share (further deteriorated from CN¥0.40 loss in 2Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Sichuan Biokin PharmaceuticalLtd Earnings Insights

Looking ahead, revenue is expected to decline by 32% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in China are expected to grow by 12%.

Performance of the Chinese Pharmaceuticals industry.

The company's shares are down 3.2% from a week ago.

Risk Analysis

It is worth noting though that we have found 1 warning sign for Sichuan Biokin PharmaceuticalLtd that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.